Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency

Abstract Introduction Dysregulated ARID1A expression is frequently detected in lung adenocarcinoma (LUAD) and mediates significant changes in cancer behaviors and a poor prognosis. ARID1A deficiency in LUAD enhances proliferation and metastasis, which could be induced by activation of the Akt signal...

Full description

Bibliographic Details
Main Authors: Dantong Sun, Feiyue Feng, Fei Teng, Tongji Xie, Jinsong Wang, Puyuan Xing, Haili Qian, Junling Li
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Cell Communication and Signaling
Subjects:
Online Access:https://doi.org/10.1186/s12964-023-01065-9
_version_ 1827983280264183808
author Dantong Sun
Feiyue Feng
Fei Teng
Tongji Xie
Jinsong Wang
Puyuan Xing
Haili Qian
Junling Li
author_facet Dantong Sun
Feiyue Feng
Fei Teng
Tongji Xie
Jinsong Wang
Puyuan Xing
Haili Qian
Junling Li
author_sort Dantong Sun
collection DOAJ
description Abstract Introduction Dysregulated ARID1A expression is frequently detected in lung adenocarcinoma (LUAD) and mediates significant changes in cancer behaviors and a poor prognosis. ARID1A deficiency in LUAD enhances proliferation and metastasis, which could be induced by activation of the Akt signaling pathway. However, no further exploration of the mechanisms has been performed. Methods Lentivirus was used for the establishment of the ARID1A knockdown (ARID1A-KD) cell line. MTS and migration/invasion assays were used to examine changes in cell behaviors. RNA-seq and proteomics methods were applied. ARID1A expression in tissue samples was determined by IHC. R software was used to construct a nomogram. Results ARID1A KD significantly promoted the cell cycle and accelerated cell division. In addition, ARID1A KD increased the phosphorylation level of a series of oncogenic proteins, such as EGFR, ErbB2 and RAF1, activated the corresponding pathways and resulted in disease progression. In addition, the bypass activation of the ErbB pathway, the activation of the VEGF pathway and the expression level changes in epithelial–mesenchymal transformation biomarkers induced by ARID1A KD contributed to the insensitivity to EGFR-TKIs. The relationship between ARID1A and the sensitivity to EGFR-TKIs was also determined using tissue samples from LUAD patients. Conclusion Loss of ARID1A expression influences the cell cycle, accelerates cell division, and promotes metastasis. EGFR-mutant LUAD patients with low ARID1A expression had poor overall survival. In addition, low ARID1A expression was associated with a poor prognosis in EGFR-mutant LUAD patients who received first-generation EGFR-TKI treatment. Video abstract
first_indexed 2024-04-09T22:46:10Z
format Article
id doaj.art-b44b859bf4da482ab95281c171696e57
institution Directory Open Access Journal
issn 1478-811X
language English
last_indexed 2024-04-09T22:46:10Z
publishDate 2023-03-01
publisher BMC
record_format Article
series Cell Communication and Signaling
spelling doaj.art-b44b859bf4da482ab95281c171696e572023-03-22T11:53:08ZengBMCCell Communication and Signaling1478-811X2023-03-0121111610.1186/s12964-023-01065-9Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiencyDantong Sun0Feiyue Feng1Fei Teng2Tongji Xie3Jinsong Wang4Puyuan Xing5Haili Qian6Junling Li7Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Introduction Dysregulated ARID1A expression is frequently detected in lung adenocarcinoma (LUAD) and mediates significant changes in cancer behaviors and a poor prognosis. ARID1A deficiency in LUAD enhances proliferation and metastasis, which could be induced by activation of the Akt signaling pathway. However, no further exploration of the mechanisms has been performed. Methods Lentivirus was used for the establishment of the ARID1A knockdown (ARID1A-KD) cell line. MTS and migration/invasion assays were used to examine changes in cell behaviors. RNA-seq and proteomics methods were applied. ARID1A expression in tissue samples was determined by IHC. R software was used to construct a nomogram. Results ARID1A KD significantly promoted the cell cycle and accelerated cell division. In addition, ARID1A KD increased the phosphorylation level of a series of oncogenic proteins, such as EGFR, ErbB2 and RAF1, activated the corresponding pathways and resulted in disease progression. In addition, the bypass activation of the ErbB pathway, the activation of the VEGF pathway and the expression level changes in epithelial–mesenchymal transformation biomarkers induced by ARID1A KD contributed to the insensitivity to EGFR-TKIs. The relationship between ARID1A and the sensitivity to EGFR-TKIs was also determined using tissue samples from LUAD patients. Conclusion Loss of ARID1A expression influences the cell cycle, accelerates cell division, and promotes metastasis. EGFR-mutant LUAD patients with low ARID1A expression had poor overall survival. In addition, low ARID1A expression was associated with a poor prognosis in EGFR-mutant LUAD patients who received first-generation EGFR-TKI treatment. Video abstracthttps://doi.org/10.1186/s12964-023-01065-9EGFR-mutant LUADEGFR-TKI resistanceARID1AMultiomics analysisCell cycle
spellingShingle Dantong Sun
Feiyue Feng
Fei Teng
Tongji Xie
Jinsong Wang
Puyuan Xing
Haili Qian
Junling Li
Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
Cell Communication and Signaling
EGFR-mutant LUAD
EGFR-TKI resistance
ARID1A
Multiomics analysis
Cell cycle
title Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
title_full Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
title_fullStr Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
title_full_unstemmed Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
title_short Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
title_sort multiomics analysis revealed the mechanisms related to the enhancement of proliferation metastasis and egfr tki resistance in egfr mutant luad with arid1a deficiency
topic EGFR-mutant LUAD
EGFR-TKI resistance
ARID1A
Multiomics analysis
Cell cycle
url https://doi.org/10.1186/s12964-023-01065-9
work_keys_str_mv AT dantongsun multiomicsanalysisrevealedthemechanismsrelatedtotheenhancementofproliferationmetastasisandegfrtkiresistanceinegfrmutantluadwitharid1adeficiency
AT feiyuefeng multiomicsanalysisrevealedthemechanismsrelatedtotheenhancementofproliferationmetastasisandegfrtkiresistanceinegfrmutantluadwitharid1adeficiency
AT feiteng multiomicsanalysisrevealedthemechanismsrelatedtotheenhancementofproliferationmetastasisandegfrtkiresistanceinegfrmutantluadwitharid1adeficiency
AT tongjixie multiomicsanalysisrevealedthemechanismsrelatedtotheenhancementofproliferationmetastasisandegfrtkiresistanceinegfrmutantluadwitharid1adeficiency
AT jinsongwang multiomicsanalysisrevealedthemechanismsrelatedtotheenhancementofproliferationmetastasisandegfrtkiresistanceinegfrmutantluadwitharid1adeficiency
AT puyuanxing multiomicsanalysisrevealedthemechanismsrelatedtotheenhancementofproliferationmetastasisandegfrtkiresistanceinegfrmutantluadwitharid1adeficiency
AT hailiqian multiomicsanalysisrevealedthemechanismsrelatedtotheenhancementofproliferationmetastasisandegfrtkiresistanceinegfrmutantluadwitharid1adeficiency
AT junlingli multiomicsanalysisrevealedthemechanismsrelatedtotheenhancementofproliferationmetastasisandegfrtkiresistanceinegfrmutantluadwitharid1adeficiency